Immunic Beheer

Beheer criteriumcontroles 3/4

De CEO Immunic is Daniel Vitt, benoemd in Apr2019, heeft een ambtstermijn van 5.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.21M, bestaande uit 48.3% salaris en 51.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.42% van de aandelen van het bedrijf, ter waarde € 441.62K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.6 jaar en 4 jaar.

Belangrijke informatie

Daniel Vitt

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	48.3%
Dienstverband CEO	5.6yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	4.6yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Daniel Vitt's beloning veranderd ten opzichte van Immunic's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$97m
Jun 30 2024	n/a	n/a	-US$95m
Mar 31 2024	n/a	n/a	-US$98m
Dec 31 2023	US$1m	US$585k	-US$94m
Sep 30 2023	n/a	n/a	-US$129m
Jun 30 2023	n/a	n/a	-US$127m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$520k	-US$120m
Sep 30 2022	n/a	n/a	-US$85m
Jun 30 2022	n/a	n/a	-US$83m
Mar 31 2022	n/a	n/a	-US$79m
Dec 31 2021	US$2m	US$399k	-US$93m
Sep 30 2021	n/a	n/a	-US$83m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$70m
Dec 31 2020	US$1m	US$381k	-US$44m
Sep 30 2020	n/a	n/a	-US$41m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$39m
Dec 31 2019	US$2m	US$202k	-US$35m

Compensatie versus markt: De totale vergoeding ($USD 1.21M ) Daniel } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 475.63K ).

Compensatie versus inkomsten: De vergoeding van Daniel is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Daniel Vitt (56 yo)

5.6yrs

Tenure

US$1,211,839

Compensatie

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic, Inc. since April 2019 and also served as its President until July 12, 2024. He is also managing director of Immunic Research GmbH in Ha...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Duane Nash	Executive Chairman	5.8yrs	US$648.93k	0.024% € 25.8k
Daniel Vitt	CEO & Director	5.6yrs	US$1.21m	0.42% € 441.6k
Glenn Whaley	Chief Financial Officer	4.6yrs	US$702.21k	0.028% € 29.9k
Andreas Muehler	Chief Medical Officer	8.3yrs	US$845.29k	0.36% € 377.0k
Jason Tardio	COO & President	less than a year	geen gegevens	geen gegevens
Hella Kohlhof	Chief Scientific Officer	7.8yrs	geen gegevens	geen gegevens
Jessica Breu	Head of Investor Relations & Communications	no data	geen gegevens	geen gegevens
Inderpal Singh	General Counsel	3.4yrs	geen gegevens	geen gegevens
Patrick Walsh	Chief Business Officer	3.1yrs	geen gegevens	geen gegevens
Werner Gladdines	Chief Development Officer	less than a year	geen gegevens	geen gegevens

4.6yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 10VA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Duane Nash	Executive Chairman	5.8yrs	US$648.93k	0.024% € 25.8k
Daniel Vitt	CEO & Director	5.6yrs	US$1.21m	0.42% € 441.6k
Barclay Phillips	Lead Independent Director	5yrs	US$99.16k	0.088% € 93.3k
Tamar Howson	Independent Director	5.1yrs	US$75.97k	0.088% € 93.3k
Jorg Neermann	Independent Director	5.6yrs	US$82.95k	0.11% € 117.2k
Paul Utz	Member of Scientific Medical Advisory Board	4yrs	geen gegevens	geen gegevens
Bruce Sands	Member of Scientific Medical Advisory Board	4yrs	geen gegevens	geen gegevens
Fred Lublin	Member of Scientific Medical Advisory Board	4yrs	geen gegevens	geen gegevens
Richard Rudick	Independent Director	1.6yrs	US$95.70k	0.097% € 102.3k
Simona Skerjanec	Director	less than a year	geen gegevens	geen gegevens
Monika Tornsen	Independent Director	2.3yrs	US$79.67k	0.041% € 43.2k

4.0yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 10VA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Immunic Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Director recently bought €95k worth of stock

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

Immunic, Inc., Annual General Meeting, Jun 11, 2024

High number of new directors

Independent Director recently bought €96k worth of stock

Recent updates

New minor risk - Market cap size

Independent Director recently bought €95k worth of stock

No longer forecast to breakeven

Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome

New major risk - Financial position

New major risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Financial position

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026

New major risk - Financial position

Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts

Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis

New minor risk - Profitability

Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023

Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

High number of new directors

Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Independent Director recently bought €96k worth of stock

Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

High number of new directors

Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022

Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investors

Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Immunic, Inc. Announces Executive Changes

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic Index

Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative Colitis

Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

Immunic, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of Its Phase I Clinical Trial of IMU-935

Immunic, Inc. Announces Enrollment of the First Patient in Its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2500 Growth Index

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

New 90-day high: €17.20

Iimmunic, Inc. Announces the Formation of a Scientific-Medical Advisory Board

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

Immunic, Inc. has completed a Follow-on Equity Offering in the amount of $90 million.

New 90-day high - €14.60

Analyse CEO-vergoeding

CEO

Tenure